Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2018

Open Access 01-12-2018 | Review

Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis

Authors: Kalina R. Atanasova, Leah R. Reznikov

Published in: Respiratory Research | Issue 1/2018

Login to get access

Abstract

The nervous system mediates key airway protective behaviors, including cough, mucus secretion, and airway smooth muscle contraction. Thus, its involvement and potential involvement in several airway diseases has become increasingly recognized. In the current review, we focus on the contribution of select neuropeptides in three distinct airway diseases: asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. We present data on some well-studied neuropeptides, as well as call attention to a few that have not received much consideration. Because mucus hypersecretion and mucus obstruction are common features of many airway diseases, we place special emphasis on the contribution of neuropeptides to mucus secretion. Finally, we highlight evidence implicating involvement of neuropeptides in mucus phenotypes in asthma, COPD and cystic fibrosis, as well as bring to light knowledge that is still lacking in the field.
Literature
1.
2.
3.
Lai H, Rogers DF. New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways. J Aerosol Med Pulm Drug Deliv. 2010;23:219–31.PubMedCrossRef
4.
Livraghi-Butrico A, Grubb BR, Wilkinson KJ, Volmer AS, Burns KA, Evans CM, O'Neal WK, Boucher RC. Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol. 2017;10:829.PubMedCrossRef
5.
Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Scroggins ME, Di Maio S, Hoffman EA, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128:997–1009.PubMedPubMedCentralCrossRef
6.
Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros. 2012;11:363–82.PubMedCrossRef
7.
Mall MA. Unplugging mucus in cystic fibrosis and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(2):S177–85.PubMed
8.
Kang JW, Lee YH, Kang MJ, Lee HJ, Oh R, Min HJ, Namkung W, Choi JY, Lee SN, Kim CH, et al. Synergistic mucus secretion by histamine and IL-4 through TMEM16A in airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2017;313:L466–76.PubMedCrossRef
9.
Gorrieri G, Scudieri P, Caci E, Schiavon M, Tomati V, Sirci F, Napolitano F, Carrella D, Gianotti A, Musante I, et al. Goblet cell hyperplasia requires high bicarbonate transport to support mucin release. Sci Rep. 2016;6:36016.PubMedPubMedCentralCrossRef
10.
Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 2017;367:537–50.PubMedCrossRef
11.
12.
13.
14.
Tokuyama K, Kuo HP, Rohde JA, Barnes PJ, Rogers DF. Neural control of goblet cell secretion in Guinea pig airways. Am J Phys. 1990;259:L108–15.
15.
Rogers DF, Dewar A. Neural control of airway mucus secretion. Biomed Pharmacother. 1990;44:447–53.PubMedCrossRef
16.
Rogers DF, Alton EW, Dewar A, Lethem MI, Barnes PJ. Impaired stimulus-evoked mucus secretion in cystic fibrosis bronchi. Exp Lung Res. 1993;19:37–53.PubMedCrossRef
17.
18.
Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 2004;4:241–50.PubMedCrossRef
19.
Wine JJ. Parasympathetic control of airway submucosal glands: central reflexes and the airway intrinsic nervous system. Auton Neurosci. 2007;133:35–54.PubMedPubMedCentralCrossRef
20.
21.
22.
Burbach JP. Neuropeptides from concept to online database www.neuropeptides.nl. Eur J Pharmacol. 2010;626:27–48.PubMedCrossRef
23.
Merighi A, Salio C, Ferrini F, Lossi L. Neuromodulatory function of neuropeptides in the normal CNS. J Chem Neuroanat. 2011;42:276–87.PubMedCrossRef
24.
Coles SJ, Bhaskar KR, O'Sullivan DD, Neill KH, Reid LM. Airway mucus: composition and regulation of its secretion by neuropeptides in vitro. CIBA Found Symp. 1984;109:40–60.PubMed
25.
26.
Deshpande DA, Penn RB. Targeting G protein-coupled receptor signaling in asthma. Cell Signal. 2006;18:2105–20.PubMedCrossRef
27.
Bradley SJ, Wiegman CH, Iglesias MM, Kong KC, Butcher AJ, Plouffe B, Goupil E, Bourgognon JM, Macedo-Hatch T, LeGouill C, et al. Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction. Proc Natl Acad Sci U S A. 2016;113:4524–9.PubMedPubMedCentralCrossRef
28.
De Swert KO, Joos GF. Extending the understanding of sensory neuropeptides. Eur J Pharmacol. 2006;533:171–81.PubMedCrossRef
29.
Joos GF, De Swert KO, Pauwels RA. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur J Pharmacol. 2001;429:239–50.PubMedCrossRef
30.
Groneberg DA, Rabe KF, Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol. 2006;533:182–94.PubMedCrossRef
31.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333–9.PubMedCrossRef
32.
Balasubramaniam AA. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides. 1997;18:445–57.PubMedCrossRef
33.
Pedragosa-Badia X, Stichel J, Beck-Sickinger AG. Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol (Lausanne). 2013;4:5.
34.
Yi M, Li H, Wu Z, Yan J, Liu Q, Ou C, Chen M. A promising therapeutic target for metabolic diseases: neuropeptide Y receptors in humans. Cell Physiol Biochem. 2018;45:88–107.PubMedCrossRef
35.
Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1–42.PubMedCrossRef
36.
Xu R, Li Q, Zhou J, Zhou X, Perelman JM, Kolosov VP. Secretoneurin induces airway mucus hypersecretion by enhancing the binding of EGF to NRP1. Cell Physiol Biochem. 2014;33:446–56.PubMedCrossRef
37.
Barnes PJ, Rodger IW, Thomson NC. Asthma, basic mechanisms and clinical management. 3rd ed. London: San Diego Academic Press; 1998.
38.
Branchfield K, Nantie L, Verheyden JM, Sui P, Wienhold MD, Sun X. Pulmonary neuroendocrine cells function as airway sensors to control lung immune response. Science. 2016;351:707–10.PubMedPubMedCentralCrossRef
39.
Sui P, Wiesner DL, Xu J, Zhang Y, Lee J, Van Dyken S, Lashua A, Yu C, Klein BS, Locksley RM, et al. Pulmonary neuroendocrine cells amplify allergic asthma responses. Science. 2018;360(6393):eaan8546.PubMedCrossRef
40.
41.
Cutz E, Yeger H, Pan J. Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. Pediatr Dev Pathol. 2007;10:419–35.PubMedCrossRef
42.
Pan J, Copland I, Post M, Yeger H, Cutz E. Mechanical stretch-induced serotonin release from pulmonary neuroendocrine cells: implications for lung development. Am J Physiol Lung Cell Mol Physiol. 2006;290:L185–93.PubMedCrossRef
43.
Yeger H, Pan J, Fu XW, Bear C, Cutz E. Expression of CFTR and cl(−) conductances in cells of pulmonary neuroepithelial bodies. Am J Physiol Lung Cell Mol Physiol. 2001;281:L713–21.PubMedCrossRef
44.
Weichselbaum M, Sparrow MP, Hamilton EJ, Thompson PJ, Knight DA. A confocal microscopic study of solitary pulmonary neuroendocrine cells in human airway epithelium. Respir Res. 2005;6:115.PubMedPubMedCentralCrossRef
45.
Soler X, Ramsdell JW. Are asthma and COPD a continuum of the same disease? J Allergy Clin Immunol Pract. 2015;3:489–95. quiz 496-487PubMedCrossRef
46.
GINA. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA); 2017. p. 2017.
47.
McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ. Diagnosis and Management of Asthma in adults: a review. JAMA. 2017;318:279–90.PubMedCrossRef
48.
Lachowicz-Scroggins ME, Yuan S, Kerr SC, Dunican EM, Yu M, Carrington SD, Fahy JV. Abnormalities in MUC5AC and MUC5B protein in airway mucus in asthma. Am J Respir Crit Care Med. 2016;194:1296–9.PubMedPubMedCentralCrossRef
49.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–61.PubMedCrossRef
50.
51.
Talbot S, Abdulnour RE, Burkett PR, Lee S, Cronin SJ, Pascal MA, Laedermann C, Foster SL, Tran JV, Lai N, et al. Silencing nociceptor neurons reduces allergic airway inflammation. Neuron. 2015;87:341–54.PubMedPubMedCentralCrossRef
52.
Fryer AD, Jacoby DB. Parainfluenza virus infection damages inhibitory M2 muscarinic receptors on pulmonary parasympathetic nerves in the Guinea-pig. Br J Pharmacol. 1991;102:267–71.PubMedPubMedCentralCrossRef
53.
Aven L, Paez-Cortez J, Achey R, Krishnan R, Ram-Mohan S, Cruikshank WW, Fine A, Ai X. An NT4/TrkB-dependent increase in innervation links early-life allergen exposure to persistent airway hyperreactivity. FASEB J. 2014;28:897–907.PubMedPubMedCentralCrossRef
54.
Hikichi M, Hashimoto S, Gon Y. Asthma and COPD overlap pathophysiology of ACO. Allergol Int. 2018;67:179–86.PubMedCrossRef
55.
Shaikh M, Sood RG, Sarkar M, Thakur V. Quantitative computed tomography (CT) assessment of emphysema in patients with severe chronic obstructive pulmonary disease (COPD) and its correlation with age, sex, pulmonary function tests, BMI, smoking, and biomass exposure. Pol J Radiol. 2017;82:760–6.PubMedPubMedCentralCrossRef
56.
Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, Gaggar A, Steele C, Tang LP, Liu B, Rowe SM. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest. 2013;144:498–506.PubMedPubMedCentralCrossRef
57.
Ramos FL, Krahnke JS, Kim V. Clinical issues of mucus accumulation in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:139–50.PubMedPubMedCentral
58.
Yamada M, Ichinose M. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities. Curr Opin Pharmacol. 2018;40:18–25.PubMedCrossRef
59.
van Gestel AJ, Steier J. Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2010;2:215–22.PubMedPubMedCentral
60.
Stewart AG, Marsh F, Waterhouse JC, Howard P. Autonomic nerve dysfunction in COPD as assessed by the acetylcholine sweat-spot test. Eur Respir J. 1994;7:1090–5.PubMed
61.
Audrit KJ, Delventhal L, Aydin O, Nassenstein C. The nervous system of airways and its remodeling in inflammatory lung diseases. Cell Tissue Res. 2017;367:571–90.PubMedCrossRef
62.
Smolonska J, Koppelman GH, Wijmenga C, Vonk JM, Zanen P, Bruinenberg M, Curjuric I, Imboden M, Thun GA, Franke L, et al. Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis. Eur Respir J. 2014;44:860–72.PubMedPubMedCentralCrossRef
63.
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–65.PubMedCrossRef
64.
65.
Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J. 2004;23:146–58.PubMedCrossRef
66.
Reznikov LR, Dong Q, Chen JH, Moninger TO, Park JM, Zhang Y, Du J, Hildebrand MS, Smith RJ, Randak CO, et al. CFTR-deficient pigs display peripheral nervous system defects at birth. Proc Natl Acad Sci U S A. 2013;110:3083–8.PubMedPubMedCentralCrossRef
67.
Pan J, Luk C, Kent G, Cutz E, Yeger H. Pulmonary neuroendocrine cells, airway innervation, and smooth muscle are altered in Cftr null mice. Am J Respir Cell Mol Biol. 2006;35:320–6.PubMedPubMedCentralCrossRef
68.
Davis PB, Kaliner M. Autonomic nervous system abnormalities in cystic fibrosis. J Chronic Dis. 1983;36:269–78.PubMedCrossRef
69.
Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol. 2000;1:392–7.PubMedCrossRef
70.
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94:265–301.PubMedPubMedCentralCrossRef
71.
Chuaychoo B, Hunter DD, Myers AC, Kollarik M, Undem BJ. Allergen-induced substance P synthesis in large-diameter sensory neurons innervating the lungs. J Allergy Clin Immunol. 2005;116:325–31.PubMedCrossRef
72.
Naline E, Devillier P, Drapeau G, Toty L, Bakdach H, Regoli D, Advenier C. Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis. 1989;140:679–86.PubMedCrossRef
73.
Fuller RW, Maxwell DL, Dixon CM, McGregor GP, Barnes VF, Bloom SR, Barnes PJ. Effect of substance P on cardiovascular and respiratory function in subjects. J Appl Physiol (1985). 1987;62:1473–9.CrossRef
74.
FROSSARD N, BARNES P. Effect of tachykinins in small human airways. Neuropeptides. 1991;19:157–61.PubMedCrossRef
75.
Lundberg JM, Martling CR, Saria A. Substance P and capsaicin-induced contraction of human bronchi. Acta Physiol Scand. 1983;119:49–53.PubMedCrossRef
76.
Choi JY, Khansaheb M, Joo NS, Krouse ME, Robbins RC, Weill D, Wine JJ. Substance P stimulates human airway submucosal gland secretion mainly via a CFTR-dependent process. J Clin Invest. 2009;119:1189–200.PubMedPubMedCentralCrossRef
77.
Bera MM, Lu B, Martin TR, Cui S, Rhein LM, Gerard C, Gerard NP. Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins. J Immunol. 2011;187:4245–55.PubMedPubMedCentralCrossRef
78.
Goravanahally MP, Hubbs AF, Fedan JS, Kashon ML, Battelli LA, Mercer RR, Goldsmith WT, Jackson MC, Cumpston A, Frazer DG, Dey RD. Diacetyl increases sensory innervation and substance P production in rat trachea. Toxicol Pathol. 2014;42:582–90.PubMedCrossRef
79.
Khansaheb M, Choi JY, Joo NS, Yang YM, Krouse M, Wine JJ. Properties of substance P-stimulated mucus secretion from porcine tracheal submucosal glands. Am J Physiol Lung Cell Mol Physiol. 2011;300:L370–9.PubMedCrossRef
80.
Phillips JE, Hey JA, Corboz MR. Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands. Br J Pharmacol. 2003;138:254–60.PubMedPubMedCentralCrossRef
81.
Chu HW, Kraft M, Krause JE, Rex MD, Martin RJ. Substance P and its receptor neurokinin 1 expression in asthmatic airways. J Allergy Clin Immunol. 2000;106:713–22.PubMedCrossRef
82.
Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, Shirato K. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med. 1995;151:613–7.PubMedCrossRef
83.
Reznikov LR, Meyerholz DK, Adam RJ, Abou Alaiwa M, Jaffer O, Michalski AS, Powers LS, Price MP, Stoltz DA, Welsh MJ. Acid-sensing Ion Channel 1a contributes to airway Hyperreactivity in mice. PLoS One. 2016;11:e0166089.PubMedPubMedCentralCrossRef
84.
Hallstrand TS, Debley JS, Farin FM, Henderson WR. Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction. J Allergy Clin Immunol. 2007;119:1092–8.PubMedPubMedCentralCrossRef
85.
86.
Van Schoor J, Joos GF, Chasson BL, Brouard RJ, Pauwels RA. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J. 1998;12:17–23.PubMedCrossRef
87.
Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, Amin D, Cohen J, Sterk PJ, Miller B, Paccaly A, et al. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007;175:450–7.PubMedCrossRef
88.
Pinter E, Pozsgai G, Hajna Z, Helyes Z, Szolcsanyi J. Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions. Br J Clin Pharmacol. 2014;77:5–20.PubMedCrossRef
89.
Tian L, Cai L, Kang J. Elevated substance P content in sputum and plasma in patients with COPD and its relationship with FEV1/FVC. Zhonghua Jie He He Hu Xi Za Zhi. 2000;23:138–40.PubMed
90.
Boschetto P, Miotto D, Bononi I, Faggian D, Plebani M, Papi A, Creminon C, De Rosa E, Fabbri LM, Mapp CE. Sputum substance P and neurokinin a are reduced during exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2005;18:199–205.PubMedCrossRef
91.
Kuo HP, Rohde JA, Barnes PJ, Rogers DF. Cigarette smoke-induced airway goblet cell secretion: dose-dependent differential nerve activation. Am J Phys. 1992;263:L161–7.
92.
93.
94.
De Swert KO, Bracke KR, Demoor T, Brusselle GG, Joos GF. Role of the tachykinin NK1 receptor in a murine model of cigarette smoke-induced pulmonary inflammation. Respir Res. 2009;10:37.PubMedPubMedCentralCrossRef
95.
Pedersen KE, Buckner CK, Meeker SN, Undem BJ. Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery. J Pharmacol Exp Ther. 2000;292:319–25.PubMed
96.
Pelaia G, Vatrella A, Gallelli L, Renda T, Caputi M, Maselli R, Marsico SA. Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006;1:321–34.PubMedPubMedCentral
97.
98.
Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, Hotchkiss JA, Zhang Y, Novikov A, Dolganov G, Fahy JV. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med. 2001;163:517–23.PubMedCrossRef
99.
Mizukami T, Tsunamura S. Some contributions to cancer control by the stimulation of the physiological protective power of the organism. Oncologia. 1962;15:312–23.PubMedCrossRef
100.
Ianowski JP, Choi JY, Wine JJ, Hanrahan JW. Substance P stimulates CFTR-dependent fluid secretion by mouse tracheal submucosal glands. Pflugers Arch. 2008;457:529–37.PubMedCrossRef
101.
O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167–80.PubMedCrossRef
102.
Patacchini R, Lecci A, Holzer P, Maggi CA. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci. 2004;25:1–3.PubMedCrossRef
103.
104.
Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets. 2006;7:1043–52.PubMedCrossRef
105.
Wang W, Li Q, Zhang J, Wu H, Yin Y, Ge Q, Zhang Y. Hemokinin-1 activates the MAPK pathway and enhances B cell proliferation and antibody production. J Immunol. 2010;184:3590–7.PubMedCrossRef
106.
Soltani A, Ewe YP, Lim ZS, Sohal SS, Reid D, Weston S, Wood-Baker R, Walters EH. Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. Eur Respir J. 2012;39:1361–7.PubMedCrossRef
107.
Kuzubova NA, Lebedeva ES, Titova ON, Fedin AN, Dvorakovskaya IV. Role of mast cells in bronchial contraction in nonallergic obstructive lung pathology. J Smooth Muscle Res. 2017;53:90–9.PubMedPubMedCentralCrossRef
108.
Ballarin A, Bazzan E, Zenteno RH, Turato G, Baraldo S, Zanovello D, Mutti E, Hogg JC, Saetta M, Cosio MG. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:233–9.PubMedCrossRef
109.
Grassin-Delyle S, Naline E, Buenestado A, Risse PA, Sage E, Advenier C, Devillier P. Expression and function of human hemokinin-1 in human and Guinea pig airways. Respir Res. 2010;11:139.PubMedPubMedCentralCrossRef
110.
Manorak W, Idahosa C, Gupta K, Roy S, Panettieri R, Ali H. Upregulation of mas-related G protein coupled receptor X2 in asthmatic lung mast cells and its activation by the novel neuropeptide hemokinin-1. Respir Res. 2018;19:1.PubMedPubMedCentralCrossRef
111.
Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45:25–39.PubMedCrossRef
112.
Groneberg D, Springer J, Fischer A. Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther. 2001;14:391–401.PubMedCrossRef
113.
Kim JS, Okamoto K, Arima S, Rubin BK. Vasoactive intestinal peptide stimulates mucus secretion, but nitric oxide has no effect on mucus secretion in the ferret trachea. J Appl Physiol (1985). 2006;101:486–91.CrossRef
114.
BARNES P. AIRWAY NEUROPEPTIDES AND ASTHMA. Trends Pharmacol Sci. 1987;8:24–7.CrossRef
115.
Coles SJ, Said SI, Reid LM. Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro. Am Rev Respir Dis. 1981;124:531–6.PubMed
116.
Ollerenshaw S, Jarvis D, Woolcock A, Sullivan C, Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med. 1989;320:1244–8.PubMedCrossRef
117.
Athari SS, Pourpak Z, Folkerts G, Garssen J, Moin M, Adcock IM, Movassaghi M, Ardestani MS, Moazzeni SM, Mortaz E. Conjugated alpha-alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice. Eur J Pharmacol. 2016;791:811–20.PubMedCrossRef
118.
Ho JJ, Crawley S, Pan PL, Farrelly ER, Kim YS. Secretion of MUC5AC mucin from pancreatic cancer cells in response to forskolin and VIP. Biochem Biophys Res Commun. 2002;294:680–6.PubMedCrossRef
119.
Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95.PubMedPubMedCentralCrossRef
120.
Linden A, Hansson L, Andersson A, Palmqvist M, Arvidsson P, Lofdahl CG, Larsson P, Lotvall J. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax. 2003;58:217–21.PubMedPubMedCentralCrossRef
121.
122.
Onoue S, Yamada S, Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides. 2007;28:1640–50.PubMedCrossRef
123.
Paulis L, Rajkovicova R, Simko F. New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? Curr Hypertens Rep. 2015;17:557.PubMedCrossRef
124.
Mandal J, Roth M, Costa L, Boeck L, Rakic J, Scherr A, Tamm M, Stolz D. Vasoactive intestinal peptide for diagnosing exacerbation in chronic obstructive pulmonary disease. Respiration. 2015;90:357–68.PubMedCrossRef
125.
Bernhard Burian SA, Nadler B, Petkov V, Block LH. Inhaled vasoactive intestinal peptide (vip) improves the 6-minute walk test and quality of life in patients with copd: the vip/copd-trial. Chest. 2006;130(4):121S.CrossRef
126.
127.
Lucchini RE, Facchini F, Turato G, Saetta M, Caramori G, Ciaccia A, Maestrelli P, Springall DR, Polak JM, Fabbri L, Mapp CE. Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am J Respir Crit Care Med. 1997;156:1963–8.PubMedCrossRef
128.
Miotto D, Boschetto P, Bononi I, Zeni E, Cavallesco G, Fabbri LM, Mapp CE. Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur Respir J. 2004;24:958–63.PubMedCrossRef
129.
Joo NS, Irokawa T, Wu JV, Robbins RC, Whyte RI, Wine JJ. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem. 2002;277:50710–5.PubMedCrossRef
130.
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32:1371–85.PubMedCrossRef
131.
Sharma RK, Addis BJ, Jeffery PK. The distribution and density of airway vasoactive intestinal polypeptide (VIP) binding sites in cystic fibrosis and asthma. Pulm Pharmacol. 1995;8:91–6.PubMedCrossRef
132.
Derand R, Montoni A, Bulteau-Pignoux L, Janet T, Moreau B, Muller JM, Becq F. Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion. Br J Pharmacol. 2004;141:698–708.PubMedPubMedCentralCrossRef
133.
Alcolado NG, Conrad DJ, Poroca D, Li M, Alshafie W, Chappe FG, Pelis RM, Anini Y, Xu Z, Hamidi S, et al. Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice. Am J Physiol Cell Physiol. 2014;307:C195–207.PubMedPubMedCentralCrossRef
134.
Bonser LR, Erle DJ. Airway mucus and asthma: the role of MUC5AC and MUC5B. J Clin Med. 2017;6:E112.PubMedCrossRef
135.
Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med. 2007;175:816–21.PubMedCrossRef
136.
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240–4.PubMedCrossRef
137.
Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983;304:129–35.PubMedCrossRef
138.
Springer J, Geppetti P, Fischer A, Groneberg DA. Calcitonin gene-related peptide as inflammatory mediator. Pulm Pharmacol Ther. 2003;16:121–30.PubMedCrossRef
139.
Qing X, Svaren J, Keith IM. mRNA expression of novel CGRP1 receptors and their activity-modifying proteins in hypoxic rat lung. Am J Physiol Lung Cell Mol Physiol. 2001;280:L547–54.PubMedCrossRef
140.
141.
Keith IM, Pelto-Huikko M, Schalling M, Hökfelt T. Calcitonin gene-related peptide and its mRNA in pulmonary neuroendocrine cells and ganglia. Histochemistry. 1991;96:311–5.PubMedCrossRef
142.
Kuo HP, Rohde JA, Tokuyama K, Barnes PJ, Rogers DF. Capsaicin and sensory neuropeptide stimulation of goblet cell secretion in Guinea-pig trachea. J Physiol. 1990;431:629–41.PubMedPubMedCentralCrossRef
143.
Webber SE, Lim JC, Widdicombe JG. The effects of calcitonin gene-related peptide on submucosal gland secretion and epithelial albumin transport in the ferret trachea in vitro. Br J Pharmacol. 1991;102:79–84.PubMedPubMedCentralCrossRef
144.
Tschirhart E, Bertrand C, Theodorsson E, Landry Y. Evidence for the involvement of calcitonin gene-related peptide in the epithelium-dependent contraction of Guinea-pig trachea in response to capsaicin. Naunyn Schmiedeberg's Arch Pharmacol. 1990;342:177–81.CrossRef
145.
Kanemura T, Tamaoki J, Horii S, Sakai N, Kobayashi K, Isono K, Takeuchi S, Takizawa T. Calcitonin gene-related peptide augments parasympathetic contraction of rabbit tracheal smooth muscle in vitro. Agents Actions. 1990;31:219–24.PubMedCrossRef
146.
147.
148.
Kay AB, Ali FR, Heaney LG, Benyahia F, Soh CP, Renz H, Lee TH, Larche M. Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics. Allergy. 2007;62:495–503.PubMedCrossRef
149.
Tan YR, Yang T, Liu SP, Xiang Y, Qu F, Liu HJ, Qin XQ. Pulmonary peptidergic innervation remodeling and development of airway hyperresponsiveness induced by RSV persistent infection. Peptides. 2008;29:47–56.PubMedCrossRef
150.
Larson SD, Plopper CG, Baker G, Tarkington BK, Decile KC, Pinkerton K, Mansoor JK, Hyde DM, Schelegle ES. Proximal airway mucous cells of ovalbumin-sensitized and -challenged Brown Norway rats accumulate the neuropeptide calcitonin gene-related peptide. Am J Physiol Lung Cell Mol Physiol. 2004;287:L286–95.PubMedCrossRef
151.
152.
153.
Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34:968–76.PubMedCrossRef
154.
Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6:871–8.PubMedPubMedCentralCrossRef
155.
González-Hernández A, Marichal-Cancino BA, Lozano-Cuenca J, López-Canales JS, Muñoz-Islas E, Ramírez-Rosas MB, Villalón CM. Heteroreceptors modulating CGRP release at neurovascular junction: potential therapeutic implications on some vascular-related diseases. Biomed Res Int. 2016;2016:2056786.PubMedPubMedCentralCrossRef
156.
Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD. A randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58:715–23.PubMedPubMedCentralCrossRef
157.
Xu H, Zhao M, Wang X. Changes of calcitonin gene-related peptide content in induced sputum from patients with COPD and asthma. Zhonghua Jie He He Hu Xi Za Zhi. 1999;22:558–61.PubMed
158.
Gu X, Karp PH, Brody SL, Pierce RA, Welsh MJ, Holtzman MJ, Ben-Shahar Y. Chemosensory functions for pulmonary neuroendocrine cells. Am J Respir Cell Mol Biol. 2014;50:637–46.PubMedPubMedCentralCrossRef
159.
Zhang S, Loch AJ, Radtke F, Egan SE, Xu K. Jagged1 is the major regulator of notch-dependent cell fate in proximal airways. Dev Dyn. 2013;242:678–86.PubMedCrossRef
160.
Springer J, Amadesi S, Trevisani M, Harrison S, Dinh QT, McGregor GP, Fischer A, Geppetti P, Groneberg DA. Effects of alpha calcitonin gene-related peptide in human bronchial smooth muscle and pulmonary artery. Regul Pept. 2004;118:127–34.PubMedCrossRef
161.
Xie W, Fisher JT, Lynch TJ, Luo M, Evans TI, Neff TL, Zhou W, Zhang Y, Ou Y, Bunnett NW, et al. CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice. J Clin Invest. 2011;121:3144–58.PubMedPubMedCentralCrossRef
162.
Sun X, Sui H, Fisher JT, Yan Z, Liu X, Cho HJ, Joo NS, Zhang Y, Zhou W, Yi Y, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest. 2010;120:3149–60.PubMedPubMedCentralCrossRef
163.
Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 2008;321:1837–41.PubMedPubMedCentralCrossRef
164.
Ostedgaard LS, Meyerholz DK, Chen JH, Pezzulo AA, Karp PH, Rokhlina T, Ernst SE, Hanfland RA, Reznikov LR, Ludwig PS, et al. The DeltaF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. Sci Transl Med. 2011;3:74ra24.PubMedPubMedCentralCrossRef
165.
Tuggle KL, Birket SE, Cui X, Hong J, Warren J, Reid L, Chambers A, Ji D, Gamber K, Chu KK, et al. Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats. PLoS One. 2014;9:e91253.PubMedPubMedCentralCrossRef
166.
167.
Groneberg DA, Folkerts G, Peiser C, Chung KF, Fischer A. Neuropeptide Y (NPY). Pulm Pharmacol Ther. 2004;17:173–80.PubMedCrossRef
168.
Cougnon N, Hudspith MJ, Munglani R. The therapeutic potential of neuropeptide Y in central nervous system disorders with special reference to pain and sympathetically maintained pain. Expert Opin Investig Drugs. 1997;6:759–69.PubMedCrossRef
169.
Wheway J, Herzog H, Mackay F. NPY and receptors in immune and inflammatory diseases. Curr Top Med Chem. 2007;7:1743–52.PubMedCrossRef
170.
Makinde TO, Steininger R, Agrawal DK. NPY and NPY receptors in airway structural and inflammatory cells in allergic asthma. Exp Mol Pathol. 2013;94:45–50.PubMedCrossRef
171.
Vatrella A, Montagnani S, Calabrese C, Parrella R, Pelaia G, Biscione GL, Corcione N, Marsico SA, Guerra G. Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents. 2010;24:425–32.PubMed
172.
Li S, Koziol-White C, Jude J, Jiang M, Zhao H, Cao G, Yoo E, Jester W, Morley MP, Zhou S, et al. Epithelium-generated neuropeptide Y induces smooth muscle contraction to promote airway hyperresponsiveness. J Clin Invest. 2016;126:1978–82.PubMedPubMedCentralCrossRef
173.
Webber SE. The effects of peptide histidine isoleucine and neuropeptide Y on mucus volume output from the ferret trachea. Br J Pharmacol. 1988;95:49–54.PubMedPubMedCentralCrossRef
174.
Merten MD, Figarella C. Neuropeptide Y and norepinephrine cooperatively inhibit human tracheal gland cell secretion. Am J Phys. 1994;266:L513–8.
175.
Dahlof C, Dahlof P, Lundberg JM, Strombom U. Elevated plasma concentration of neuropeptide Y and low level of circulating adrenaline in elderly asthmatics during rest and acute severe asthma. Pulm Pharmacol. 1988;1:3–6.PubMedCrossRef
176.
Lu Y, Ho R, Lim TK, Kuan WS, Goh DY, Mahadevan M, Sim TB, Van Bever HP, Larbi A, Ng TP. Neuropeptide Y may mediate psychological stress and enhance TH2 inflammatory response in asthma. J Allergy Clin Immunol. 2015;135:1061–1063.e1064.PubMedCrossRef
177.
Lu Y, Ho RC. An association between neuropeptide Y levels and leukocyte subsets in stress-exacerbated asthmatic mice. Neuropeptides. 2016;57:53–8.PubMedCrossRef
178.
Macia L, Rao PT, Wheway J, Sierro F, Mackay F, Herzog H. Y1 signalling has a critical role in allergic airway inflammation. Immunol Cell Biol. 2011;89:882–8.PubMedCrossRef
179.
Li S, Wang Y, Zhang Y, Lu MM, DeMayo FJ, Dekker JD, Tucker PW, Morrisey EE. Foxp1/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. Development. 2012;139:2500–9.PubMedPubMedCentralCrossRef
180.
Chanez P, Springall D, Vignola AM, Moradoghi-Hattvani A, Polak JM, Godard P, Bousquet J. Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med. 1998;158:985–90.PubMedCrossRef
181.
Lacroix JS, Mosimann BL. Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients. J Allergy Clin Immunol. 1996;98:611–6.PubMedCrossRef
182.
183.
Borbély E, Scheich B, Helyes Z. Neuropeptides in learning and memory. Neuropeptides. 2013;47:439–50.PubMedCrossRef
184.
Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol. 2013;305:L530–41.PubMedPubMedCentralCrossRef
185.
Wu ZX, Benders KB, Hunter DD, Dey RD. Early postnatal exposure of mice to side-steam tobacco smoke increases neuropeptide Y in lung. Am J Physiol Lung Cell Mol Physiol. 2012;302:L152–9.PubMedCrossRef
186.
Thangaratnarajah C, Dinger K, Vohlen C, Klaudt C, Nawabi J, Lopez Garcia E, Kwapiszewska G, Dobner J, Nusken KD, van Koningsbruggen-Rietschel S, et al. Novel role of NPY in neuroimmune interaction and lung growth after intrauterine growth restriction. Am J Physiol Lung Cell Mol Physiol. 2017;313:L491–506.PubMedCrossRef
187.
Grubek-Jaworska H, Paplinska M, Hermanowicz-Salamon J, Bialek-Gosk K, Dabrowska M, Grabczak E, Domagala-Kulawik J, Stepien J, Chazan R. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration. 2012;84:101–7.PubMedCrossRef
188.
Kirkham S, Kolsum U, Rousseau K, Singh D, Vestbo J, Thornton DJ. MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:1033–9.PubMedPubMedCentralCrossRef
189.
Crnkovic S, Egemnazarov B, Jain P, Seay U, Gattinger N, Marsh LM, Balint Z, Kovacs G, Ghanim B, Klepetko W, et al. NPY/Y(1) receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension. Br J Pharmacol. 2014;171:3895–907.PubMedPubMedCentralCrossRef
190.
Meisler MH, Spence JE, Dixon JE, Caldwell RM, Minth CD, Beaudet AL. Exclusion of close linkage between the loci for cystic fibrosis and neuropeptide Y on human chromosome 7. Cytogenet Cell Genet. 1987;44:175–6.PubMedCrossRef
191.
Pfister S, Weber T, Hartig W, Schwerdel C, Elsaesser R, Knuesel I, Fritschy JM. Novel role of cystic fibrosis transmembrane conductance regulator in maintaining adult mouse olfactory neuronal homeostasis. J Comp Neurol. 2015;523:406–30.PubMedCrossRef
192.
Fleming MS, Ramos D, Han SB, Zhao J, Son YJ, Luo W. The majority of dorsal spinal cord gastrin releasing peptide is synthesized locally whereas neuromedin B is highly expressed in pain- and itch-sensing somatosensory neurons. Mol Pain. 2012;8:52.PubMedPubMedCentralCrossRef
193.
Siegfried JM, Guentert PJ, Gaither AL. Effects of bombesin and gastrin-releasing peptide on human bronchial epithelial cells from a series of donors: individual variation and modulation by bombesin analogs. Anat Rec. 1993;236:241–7.PubMedCrossRef
194.
Miller YE. Bombesin-like peptides: from frog skin to human lung. Am J Respir Cell Mol Biol. 1990;3:189–90.PubMedCrossRef
195.
Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15:58–64.PubMedPubMedCentralCrossRef
196.
Qin XQ, Qu XP. Extraintestinal roles of bombesin-like peptides and their receptors: lung. Curr Opin Endocrinol Diabetes Obes. 2013;20:22–6.PubMedCrossRef
197.
Ramos-Alvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, Coy DH, Jensen RT. Insights into bombesin receptors and ligands: highlighting recent advances. Peptides. 2015;72:128–44.PubMedPubMedCentralCrossRef
198.
Guo M, Qu X, Qin XQ. Bombesin-like peptides and their receptors: recent findings in pharmacology and physiology. Curr Opin Endocrinol Diabetes Obes. 2015;22:3–8.PubMedCrossRef
199.
Lach E, Haddad EB, Gies JP. Contractile effect of bombesin on Guinea pig lung in vitro: involvement of gastrin-releasing peptide-preferring receptors. Am J Phys. 1993;264:L80–6.CrossRef
200.
Baraniuk JN, Lundgren JD, Shelhamer JH, Kaliner MA. Gastrin releasing peptide (GRP) binding sites in human bronchi. Neuropeptides. 1992;21:81–4.PubMedCrossRef
201.
Lundgren JD, Baraniuk JN, Ostrowski NL, Kaliner MA, Shelhamer JH. Gastrin-releasing peptide stimulates glycoconjugate release from feline trachea. Am J Phys. 1990;258:L68–74.
202.
Eisner MD, Klein J, Hammond SK, Koren G, Lactao G, Iribarren C. Directly measured second hand smoke exposure and asthma health outcomes. Thorax. 2005;60:814–21.PubMedPubMedCentralCrossRef
203.
Siegfried JM, DeMichele MA, Hunt JD, Davis AG, Vohra KP, Pilewski JM. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. Am J Respir Crit Care Med. 1997;156:358–66.PubMedCrossRef
204.
Shriver SP, Bourdeau HA, Gubish CT, Tirpak DL, Davis AL, Luketich JD, Siegfried JM. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst. 2000;92:24–33.PubMedCrossRef
205.
Subramaniam M, Bausch C, Twomey A, Andreeva S, Yoder BA, Chang L, Crapo JD, Pierce RA, Cuttitta F, Sunday ME. Bombesin-like peptides modulate alveolarization and angiogenesis in bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2007;176:902–12.PubMedPubMedCentralCrossRef
206.
Perez Tarazona S, Solano Galan P, Bartoll Alguacil E, Alfonso Diego J. Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: a systematic review. Allergol Immunopathol (Madr). 2018;46:87–98.CrossRef
207.
Xu Q, Chen LX, Ran DH, Xie WY, Li Q, Zhou XD. Bombesin receptor-activated protein regulates neutrophil elastase-induced mucin5AC hypersecretion in human bronchial epithelial cells. Exp Cell Res. 2017;357:145–54.PubMedCrossRef
208.
Nadel JA, Takeyama K, Agusti C. Role of neutrophil elastase in hypersecretion in asthma. Eur Respir J. 1999;13:190–6.PubMedCrossRef
209.
Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9:1738–41.PubMedCrossRef
210.
Lemaire I. Bombesin-related peptides modulate interleukin-1 production by alveolar macrophages. Neuropeptides. 1991;20:217–23.PubMedCrossRef
211.
Belvisi MG, Stretton CD, Barnes PJ. Bombesin-induced bronchoconstriction in the Guinea pig: mode of action. J Pharmacol Exp Ther. 1991;258:36–41.PubMed
212.
Kim JS, McKinnis VS, White SR. Migration of Guinea pig airway epithelial cells in response to bombesin analogues. Am J Respir Cell Mol Biol. 1997;16:259–66.PubMedCrossRef
213.
Roos AB, Berg T, Nord M. A relationship between epithelial maturation, bronchopulmonary dysplasia, and chronic obstructive pulmonary disease. Pulm Med. 2012;2012:196194.PubMedPubMedCentralCrossRef
214.
Johnson DE, Wobken JD, Landrum BG. Changes in bombesin, calcitonin, and serotonin immunoreactive pulmonary neuroendocrine cells in cystic fibrosis and after prolonged mechanical ventilation. Am Rev Respir Dis. 1988;137:123–31.PubMedCrossRef
215.
Wolf P, Hall C, Kilbourn JP. Demonstration of calcitonin and calmodulin by immunoperoxidase in the cystic fibrosis lung. Chest. 1986;89:327–30.PubMedCrossRef
216.
Helle KB, Metz-Boutigue MH, Cerra MC, Angelone T. Chromogranins: from discovery to current times. Pflugers Arch. 2018;470:143–54.PubMedCrossRef
217.
Yajima N, Wada R, Yamagishi S, Mizukami H, Itabashi C, Yagihashi S. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Hum Pathol. 2005;36:1217–25.PubMedCrossRef
218.
Al-Risi ES, Al-Essry FS, Mula-Abed WS. Chromogranin a as a biochemical marker for neuroendocrine tumors: a single center experience at Royal Hospital, Oman. Oman Med J. 2017;32:365–70.PubMedPubMedCentralCrossRef
219.
Elshafie O, Nair J, Busaidi M, Riyami B, Hussein S, Woodhouse N. Chromogranin-a levels and refractory bronchospasm in interstitial lung disease: a preliminary report on the Favourable response to octreotide. British J Med Medical Res. 2015;7:705–10.CrossRef
220.
Dunzendorfer S, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Secretoneurin, a novel neuropeptide, is a potent chemoattractant for human eosinophils. Blood. 1998;91:1527–32.PubMed
221.
222.
Kirchmair R, Marksteiner J, Troger J, Mahata SK, Mahata M, Donnerer J, Amann R, Fischer-Colbrie R, Winkler H, Saria A. Human and rat primary C-fibre afferents store and release secretoneurin, a novel neuropeptide. Eur J Neurosci. 1994;6:861–8.PubMedCrossRef
223.
Zhao E, Basak A, Wong AO, Ko W, Chen A, Lopez GC, Grey CL, Canosa LF, Somoza GM, Chang JP, Trudeau VL. The secretogranin II-derived peptide secretoneurin stimulates luteinizing hormone secretion from gonadotrophs. Endocrinology. 2009;150:2273–82.PubMedCrossRef
224.
Sorhaug S, Langhammer A, Waldum HL, Hveem K, Steinshamn S. Increased serum levels of chromogranin a in male smokers with airway obstruction. Eur Respir J. 2006;28:542–8.PubMedCrossRef
225.
Ottesen AH, Louch WE, Carlson CR, Landsverk OJB, Kurola J, Johansen RF, Moe MK, Aronsen JM, Hoiseth AD, Jarstadmarken H, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. 2015;65:339–51.PubMedCrossRef
226.
Pan J, Bear C, Farragher S, Cutz E, Yeger H. Cystic fibrosis transmembrane conductance regulator modulates neurosecretory function in pulmonary neuroendocrine cell-related tumor cell line models. Am J Respir Cell Mol Biol. 2002;27:553–60.PubMedCrossRef
227.
Hill DB, Button B. Establishment of respiratory air-liquid interface cultures and their use in studying mucin production, secretion, and function. Methods Mol Biol. 2012;842:245–58.PubMedCrossRef
228.
Ianowski JP, Choi JY, Wine JJ, Hanrahan JW. Mucus secretion by single tracheal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice. J Physiol. 2007;580:301–14.PubMedPubMedCentralCrossRef
229.
Hoegger MJ, Fischer AJ, McMenimen JD, Ostedgaard LS, Tucker AJ, Awadalla MA, Moninger TO, Michalski AS, Hoffman EA, Zabner J, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science. 2014;345:818–22.PubMedPubMedCentralCrossRef
230.
231.
Yang N, Garcia MA, Quinton PM. Normal mucus formation requires cAMP-dependent HCO3- secretion and Ca2+−mediated mucin exocytosis. J Physiol. 2013;591:4581–93.PubMedPubMedCentralCrossRef
232.
Samarasinghe AE, Hoselton SA, Schuh JM. The absence of VPAC2 leads to aberrant antibody production in aspergillus fumigatus sensitized and challenged mice. Peptides. 2011;32:131–7.PubMedCrossRef
233.
Nieber K, Baumgarten CR, Rathsack R, Furkert J, Oehme P, Kunkel G, Substance P. Beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma. J Allergy Clin Immunol. 1992;90:646–52.PubMedCrossRef
234.
Ollerenshaw SL, Jarvis D, Sullivan CE, Woolcock AJ. Substance P immunoreactive nerves in airways from asthmatics and nonasthmatics. Eur Respir J. 1991;4:673–82.PubMed
235.
Dinh QT, Mingomataj E, Quarcoo D, Groneberg DA, Witt C, Klapp BF, Braun A, Fischer A. Allergic airway inflammation induces tachykinin peptides expression in vagal sensory neurons innervating mouse airways. Clin Exp Allergy. 2005;35:820–5.PubMedCrossRef
236.
Dinh QT, Groneberg DA, Witt C, Peiser C, Cifuentes LB, Frossard N, Klapp BF, Fischer A. Expression of tyrosine hydroxylase and neuropeptide tyrosine in mouse sympathetic airway-specific neurons under normal situation and allergic airway inflammation. Clin Exp Allergy. 2004;34:1934–41.PubMedCrossRef
237.
Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017;18:26.PubMedPubMedCentralCrossRef
238.
Cusack D, Cannon D, Skrabanek P, Powell D. Substance P plasma levels in pregnancy and in various clinical disorders. Horm Metab Res. 1979;11:448–51.PubMedCrossRef
239.
Trout L, Corboz MR, Ballard ST. Mechanism of substance P-induced liquid secretion across bronchial epithelium. Am J Physiol Lung Cell Mol Physiol. 2001;281:L639–45.PubMedCrossRef
240.
Canning BJ. Neurokinin3 receptor regulation of the airways. Vasc Pharmacol. 2006;45:227–34.CrossRef
241.
242.
Edgerton MD, Chabert C, Chollet A, Arkinstall S. Palmitoylation but not the extreme amino-terminus of Gq alpha is required for coupling to the NK2 receptor. FEBS Lett. 1994;354:195–9.PubMedCrossRef
243.
Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J Biol Chem. 1992;267:2437–42.PubMed
244.
Gallacher DV, Hanley MR, Petersen OH, Roberts ML, Squire-Pollard LG, Yule DI. Substance P and bombesin elevate cytosolic Ca2+ by different molecular mechanisms in a rat pancreatic acinar cell line. J Physiol. 1990;426:193–207.PubMedPubMedCentralCrossRef
245.
Hanley MR, Lee CM, Michell RH, Jones LM. Similar effects of substance P and related peptides on salivation and on phosphatidylinositol turnover in rat salivary glands. Mol Pharmacol. 1980;18:78–83.PubMed
246.
Komabayashi T, Yakata A, Izawa T, Suda K, Noguchi M, Tsuboi M. Substance P-induced diacylglycerol formation in rat parotid acinar cells. Eur J Pharmacol. 1991;207:329–35.PubMedCrossRef
247.
Groneberg DA, Hartmann P, Dinh QT, Fischer A. Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab Investig. 2001;81:749–55.PubMedCrossRef
248.
249.
Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther. 2009;121:294–316.PubMedCrossRef
250.
Mak JC, Barnes PJ. Autoradiographic localization of calcitonin gene-related peptide (CGRP) binding sites in human and Guinea pig lung. Peptides. 1988;9:957–63.PubMedCrossRef
251.
Drissi H, Lasmoles F, Le Mellay V, Marie PJ, Lieberherr M. Activation of phospholipase C-beta1 via Galphaq/11 during calcium mobilization by calcitonin gene-related peptide. J Biol Chem. 1998;273:20168–74.PubMedCrossRef
252.
Kokkoris S, Andrews P, Webb DJ. Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage. Front Endocrinol (Lausanne). 2012;3:135.
253.
Parker SL, Balasubramaniam A. Neuropeptide Y Y2 receptor in health and disease. Br J Pharmacol. 2008;153:420–31.PubMedCrossRef
254.
Misra S, Murthy KS, Zhou H, Grider JR. Coexpression of Y1, Y2, and Y4 receptors in smooth muscle coupled to distinct signaling pathways. J Pharmacol Exp Ther. 2004;311:1154–62.PubMedCrossRef
255.
Motulsky HJ, Michel MC. Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am J Phys. 1988;255:E880–5.
256.
Pellieux C, Sauthier T, Domenighetti A, Marsh DJ, Palmiter RD, Brunner HR, Pedrazzini T. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A. 2000;97:1595–600.PubMedPubMedCentralCrossRef
257.
De la Fuente M, Del Rio M, Hernanz A. Stimulation of natural killer and antibody-dependent cellular cytotoxicity activities in mouse leukocytes by bombesin, gastrin-releasing peptide and neuromedin C: involvement of cyclic AMP, inositol 1,4,5-trisphosphate and protein kinase C. J Neuroimmunol. 1993;48:143–50.PubMedCrossRef
Metadata
Title
Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis
Authors
Kalina R. Atanasova
Leah R. Reznikov
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2018
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-018-0846-4

Other articles of this Issue 1/2018

Respiratory Research 1/2018 Go to the issue

Research

Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation

Research

Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)

Research

Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis

Research

Human antigen R enhances the epithelial-mesenchymal transition via regulation of ZEB-1 in the human airway epithelium

Letter to the Editor

Pulmonary aspiration in preschool children with cystic fibrosis

Research

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits